SAB Biotherapeutics, Inc.
SABS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001833214
No open-market purchases or sales by SAB Biotherapeutics, Inc. insiders were filed in the last 90 days; 87 institutions reported holding it in 13F filings for Q2 2026, worth $266.8M in total; no superinvestor holds it.
Other share classesSABSW
13F holders, Q2 2025
Institutional positions in SAB Biotherapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 25
- −1 vs. Q1 2025
- Shares held
- 1.92M
- −285.7K (−12.9%) vs. Q1 2025
- Total value
- $3.37M
- +$375.1K (+12.5%) vs. Q1 2025
- New holders
- 3
- 6 more added
- Sold out
- 4
- 4 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SABS on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 87 | $266.8M |
| Q1 2026 | 76 | $265.0M |
| Q4 2025 | 48 | $135.9M |
| Q3 2025 | 34 | $56.3M |
| Q2 2025 | 25 | $3.37M |
| Q1 2025 | 26 | $2.99M |
| Q4 2024 | 25 | $10.1M |
| Q3 2024 | 25 | $8.48M |
| Q2 2024 | 22 | $9.69M |
| Q1 2024 | 24 | $15.2M |
| Q4 2023 | 42 | $24.5M |
| Q3 2023 | 34 | $2.41M |
| Q2 2023 | 38 | $3.28M |
| Q1 2023 | 39 | $1.71M |
| Q4 2022 | 38 | $2.42M |
| Q3 2022 | 40 | $2.32M |
| Q2 2022 | 37 | $4.45M |
| Q1 2022 | 27 | $6.71M |
| Q4 2021 | 34 | $25.4M |
| Q3 2021 | 1 | $605.0K |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding SAB Biotherapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BVF Inc | 917,826 | $1.61M | 0.06% | 00.0% | Unchanged |
| Sessa Capital IM, L.P. | 458,457 | $804.6K | 0.02% | 00.0% | Unchanged |
| Vanguard Group Inc | 282,371 | $494.1K | 0.00% | +4,861+1.8% | Added |
| Geode Capital Management, LLC | 84,772 | $148.4K | 0.00% | +87+0.1% | Added |
| Pathstone Holdings, LLC | 50,650 | $88.9K | 0.00% | 00.0% | Unchanged |
| Kovitz Investment Group Partners, LLC | 19,201 | $33.7K | 0.00% | 00.0% | Unchanged |
| First PREMIER Bank | 18,986 | $33.0K | 0.01% | 00.0% | Unchanged |
| Citadel Advisors LLC | 17,095 | $29.9K | 0.00% | +17,095 | New |
| Kestra Advisory Services, LLC | 11,930 | $20.9K | 0.00% | 00.0% | Unchanged |
| Creative Planning | 11,852 | $20.8K | 0.00% | +11,852 | New |
| Northern Trust Corp | 11,387 | $20.0K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 11,030 | $19.4K | 0.00% | +1,000+10.0% | Added |
| UBS Group AG | 10,658 | $18.7K | 0.00% | +10,580+13,564.1% | Added |
| BlackRock, Inc. | 7,006 | $12.3K | 0.00% | −15,295−68.6% | Reduced |
| Advisor Group Holdings, Inc. | 4,937 | $8.64K | 0.00% | −10−0.2% | Reduced |
| Sachetta, LLC | 4,100 | $7.20K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 726 | $1.27K | 0.00% | +692+2,035.3% | Added |
| MAI Capital Management | 217 | $381 | 0.00% | 00.0% | Unchanged |
| Gs Investments, Inc. | 200 | $351 | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 168 | $295 | 0.00% | −281−62.6% | Reduced |
| JPMorgan Chase & Co | 87 | $152 | 0.00% | −16−15.5% | Reduced |
| Bank of America Corp | 73 | $128 | 0.00% | +6+9.0% | Added |
| Harbour Investments, Inc. | 50 | $88 | 0.00% | 00.0% | Unchanged |
| SBI Securities Co., Ltd. | 50 | $88 | 0.00% | 00.0% | Unchanged |
| Raymond James Financial Inc | 45 | $79 | 0.00% | +45 | New |
| HB Wealth Management, LLC | 0 | $0 | 0.00% | −263,200−100.0% | Sold out |
| Silver Oak Securities, Inc | 0 | $0 | 0.00% | −20,188−100.0% | Sold out |
| XTX Topco Ltd | 0 | $0 | 0.00% | −16,555−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −16,351−100.0% | Sold out |